Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.
Open Access
- 1 April 1976
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 57 (4) , 875-884
- https://doi.org/10.1172/jci108364
Abstract
To study the individual effects of glucagon and growth hormone on human carbohydrate and lipid metabolism, endogenous secretion of both hormones was simultaneously suppressed with somatostatin and physiologic circulating levels of one or the other hormone were reproduced by exogenous infusion. The interaction of these hormones with insulin was evaluated by performing these studies in juvenile-onset, insulin-deficient diabetic subjects both during infusion of insulin and after its withdrawal. Infusion of glucagon (1 ng/kg-min) during suppression of its endogenous secretion with somatostatin produced circulating hormone levels of approximately 200 pg/ml. When glucagon was infused along with insulin, plasma glucose levels rose from 94 +/- 8 to 126 +/- 12 mg/100 ml over 1 h (P less than 0.01); growth hormone, beta-hydroxy-butyrate, alanine, FFA, and glycerol levels did not change. When insulin was withdrawn, plasma glucose, beta-hydroxybutyrate, FFA, and glycerol all rose to higher levels (P less than 0.01) than those observed under similar conditions when somatostatin alone had been infused to suppress glucagon secretion. Thus, under appropriate conditions, physiologic levels of glucagon can stimulate lipolysis and cause hyperketonemia and hyperglycemia in man; insulin antagonizes the lipolytic and ketogenic effects of glucagon more effectively than the hyperglycemic effect. Infusion of growth hormone (1 mug/kg-h) during suppression of its endogenous secretion with somastostatin produced circulating hormone levels of approximately 6 ng/ml. When growth hormone was administered along with insulin, no effects were observed. After insulin was withdrawn, plasma beta-hydroxybutyrate, glycerol, and FFA all rose to higher levels (P less than 0.01) than those observed during infusion of somatostatin alone when growth hormone secretion was suppressed; no difference in plasma glucose, alanine, and glucagon levels was evident. Thus, under appropriate conditions, physiologic levels of growth hormone can augment lipolysis and ketonemia in man, but these actions are ordinarily not apparent in the presence of physiologic levels of insulin.Keywords
This publication has 47 references indexed in Scilit:
- GLUCAGON CONTROL OF FASTING GLUCOSE IN MANThe Lancet, 1974
- Effects of Glucagon on Lipolysis and Ketogenesis in Normal and Diabetic MenJournal of Clinical Investigation, 1974
- Role of Lipolytic and Glucocorticoid Hormones in the Development of Diabetic KetosisDiabetes, 1972
- Metabolic response to human growth hormone during prolonged starvationJournal of Clinical Investigation, 1971
- Effect of Growth Hormone and Dexamethasone on Lipolysis and Metabolism in Isolated Fat Cells of the RatJournal of Biological Chemistry, 1965
- Effect of Human Growth Hormone on Muscle and Adipose Tissue Metabolism in the Forearm of Man *Journal of Clinical Investigation, 1965
- Elevation of Plasma Epinephrine Levels Produced by Glucagonin VivoEndocrinology, 1963
- Diabetogenic and hypoglycemic effects of human growth hormone.1960
- METABOLIC EFFECTS OF GLUCAGON IN HUMAN SUBJECTS1960
- EFFECT OF GROWTH HORMONE ON PLASMA FATTY ACIDS*Journal of Clinical Investigation, 1959